<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Galantamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Galantamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Galantamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12505" href="/d/html/12505.html" rel="external">see "Galantamine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F175172"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Razadyne ER [DSC];</li>
<li>Razadyne [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867020"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Galantamine;</li>
<li>Auro-Galantamine ER;</li>
<li>Mar-Galantamine ER [DSC];</li>
<li>MYLAN-Galantamine ER;</li>
<li>PAT-Galantamine ER;</li>
<li>PMS-Galantamine ER</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F175199"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor (Central)</li></ul></div>
<div class="block doa drugH1Div" id="F175176"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3041b3d-3f11-47c1-815e-01b475c1f691">Alzheimer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Alzheimer disease, mild to moderate:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate-release tablet or solution:</i>
<b>Oral:</b> Initial: 4 mg twice daily for 4 weeks; if tolerated, increase to 8 mg twice daily for ≥4 weeks; if tolerated, increase to 12 mg twice daily. Range: 16 to 24 mg daily in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended-release capsule:</i>
<b>Oral:</b> Initial: 8 mg once daily for 4 weeks; if tolerated, increase to 16 mg once daily for ≥4 weeks; if tolerated, increase to 24 mg once daily. Range: 16 to 24 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If therapy is interrupted for ≥3 days, restart at the lowest dose and increase to current dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Alzheimer disease, severe (off-label use): Oral:</b> Immediate-release tablet: Initial: 4 mg twice daily for 4 weeks; if tolerated, increase to 8 mg twice daily for ≥4 weeks; if tolerated, increase to 12 mg twice daily. May decrease to 8 mg twice daily if the target dose is not tolerated. Range: 16 to 24 mg daily in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19042161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19042161'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4056565c-8c10-4091-803a-ca63fba68729">Dementia with Lewy bodies and Parkinson disease dementia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dementia with Lewy bodies and Parkinson disease dementia (off-label use):</b>
<b>Note:</b> In patients with mild or moderate dementia with Lewy bodies, consider galantamine therapy only in patients who do not tolerate donepezil and rivastigmine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> American Psychiatric Association recommends dosing and titration similar to those for patients with Alzheimer disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18340692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18340692'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c37ada3-619b-4368-b14e-0fdb5df75333">Vascular dementia, comorbid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vascular dementia, comorbid (off-label use): </b>
<b>Note:</b> For use in patients with suspected comorbid Alzheimer disease, Parkinson disease dementia, or dementia with Lewy bodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;margin-right:2em;">
<b>Oral:</b> Initial: 4 mg twice daily for 4 weeks; increase to 8 mg twice daily for 4 weeks; if tolerated, increase to 12 mg twice daily. Range: 16 to 24 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17664404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17664404'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Conversion from immediate release to extended release formulation:</i></b> Patients may be switched from the immediate-release formulation to the extended-release formulation by taking the last immediate-release dose in the evening and beginning the extended-release dose the following morning; the same total daily dose should be used.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Conversion to galantamine from other cholinesterase inhibitors:</i></b> Patients experiencing poor tolerability with donepezil or rivastigmine should wait until side effects subside or allow a 7-day washout period prior to beginning galantamine. Patients not experiencing side effects with donepezil or rivastigmine may begin galantamine therapy the day immediately following discontinuation of previous therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11396870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11396870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991207"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (CrCl 9 to 59 mL/minute): Maximum dose: 16 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (CrCl &lt;9 mL/minute): Use is not recommended</p></div>
<div class="block doha drugH1Div" id="F50988397"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer’s labeling; however, single-dose galantamine pharmacokinetics were similar to that observed in healthy subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Maximum dose: 16 mg/day</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended</p></div>
<div class="block doe drugH1Div" id="F175177"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; adjust dose with caution in patients with low body weight and/or serious comorbidities. </p></div>
<div class="block adr drugH1Div" id="F175140"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Nausea (21%), vomiting (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (1%), syncope (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (2%), abdominal pain (4%), decreased appetite (7%), diarrhea (7%), dyspepsia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (4%), dizziness (8%), drowsiness (2%), falling (4%), fatigue (4%), headache (7%), lethargy (1%), malaise (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (1%), tremor (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Laceration (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: First degree atrioventricular block, flushing, hypotension, palpitations, sinus bradycardia, supraventricular extrasystole</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, retching</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypersomnia, myasthenia, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Anorexia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Complete atrioventricular block, hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme, skin rash, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug-induced extrapyramidal reaction, hallucination, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p></div>
<div class="block coi drugH1Div" id="F175153"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to galantamine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to other tertiary alkaloids.</p></div>
<div class="block war drugH1Div" id="F175138"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extrapyramidal effects: May exacerbate extrapyramidal symptoms due to an increase in cholinergic tone.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Skin reactions including Stevens-Johnson syndrome, acute generalized exanthematous pustulosis and erythema multiforme have been reported. Treatment discontinuation may be necessary if skin reaction occurs; if rash is suspected to be drug related, do not resume galantamine and consider alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vagotonic effects: Cholinesterase inhibitors may have vagotonic effects which may cause bradycardia and/or heart block with or without a history of cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight loss: Weight loss has been observed; monitor body weight.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac conduction abnormalities: Use with caution in patients with sick-sinus syndrome, bradycardia, or conduction abnormalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild to moderate liver impairment; not recommended in severe impairment. Dose adjustment recommended in moderate impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous history or NSAID use); may increase gastric acid secretion. Monitor for symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with moderate renal impairment; not recommended in severe impairment (CrCl &lt;9 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with COPD and/or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction; cholinomimetics may cause or worsen outflow obstructions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Limited safety data in patients ≥85 years of age. Use with caution particularly in elderly patients with low body weight and/or serious comorbidities; adjust dose with caution.</p></div>
<div class="block foc drugH1Div" id="F175148"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrobromide [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Razadyne ER: 8 mg [DSC], 16 mg [DSC], 24 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mg, 16 mg, 24 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrobromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrobromide [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Razadyne: 4 mg [DSC], 8 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Razadyne: 12 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg, 12 mg</p></div>
<div class="block geq drugH1Div" id="F175134"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422231"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Galantamine Hydrobromide ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $6.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 mg (per each): $6.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24 mg (per each): $6.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Galantamine Hydrobromide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $3.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Galantamine Hydrobromide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $3.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $3.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 mg (per each): $3.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867021"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrobromide [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PAT-Galantamine ER: 8 mg, 16 mg, 24 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mg, 16 mg, 24 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrobromide [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg</p></div>
<div class="block adm drugH1Div" id="F175150"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer solution or tablet with breakfast and dinner; administer ER capsule with breakfast. If therapy is interrupted for ≥3 days, restart at the lowest dose and increase to current dose. If using oral solution, mix dose with 3 to 4 ounces of any nonalcoholic beverage; mix well and drink immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Capsule, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No information available from manufacturer regarding safety of opening capsules. Consider switching to IR tablets or oral solution.</p></div>
<div class="block use drugH1Div" id="F175149"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alzheimer disease, mild to moderate:</b> Treatment of mild to moderate dementia of Alzheimer disease</p></div>
<div class="block off-label drugH1Div" id="F25725979"><span class="drugH1">Use: Off-Label: Adult</span><p>Alzheimer disease, severe; Dementia with Lewy bodies and Parkinson disease dementia; Vascular dementia, comorbid</p></div>
<div class="block mst drugH1Div" id="F175207"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Razadyne [DSC] may be confused with Rozerem</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Reminyl [Canada and multiple international markets] may be confused with Amarel brand name for glimepiride [France]; Amaryl brand name for glimepiride [US, Canada, and multiple international markets]; Robinul brand name for glycopyrrolate [US and multiple international markets].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F175193"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F175142"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Galantamine may enhance the neurotoxic (central) effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Chlorprothixene. Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Galantamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Galantamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F175156"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F16265817"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if galantamine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F175157"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administration with food is preferred, but not required; should be taken with breakfast and dinner (tablet or solution) or with breakfast (capsule).</p></div>
<div class="block mop drugH1Div" id="F175146"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mental status; body weight, symptoms of GI intolerance, symptoms of active or occult GI bleeding</p></div>
<div class="block pha drugH1Div" id="F175137"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Centrally-acting cholinesterase inhibitor (competitive and reversible). It elevates acetylcholine in cerebral cortex by slowing the degradation of acetylcholine. Modulates nicotinic acetylcholine receptor to increase acetylcholine from surviving presynaptic nerve terminals. May increase glutamate and serotonin levels.</p></div>
<div class="block phk drugH1Div" id="F175152"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 175 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 18% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic metabolism primarily via CYP2D6 to O-desmethyl-galantamine and 3A4 to galantamine-N-oxide; the activity of galantamine metabolites is not considered to be clinically relevant (Farlow 2003; Scott 2000)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~90%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~7 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Immediate release: 1 hour (2.5 hours with food); extended release: 4.5-5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (20%)</p></div>
<div class="block phksp drugH1Div" id="F51196088"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased 37% and 67% in moderate and severe renal function impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Cl decreased about 25% in moderate (Child-Pugh score 7 to 9) hepatic function impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Concentrations are about 30% to 40% higher.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Cl is about 20% lower in women than in men.</p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 poor metabolizers: There is an approximate 35% increase in AUC of unchanged drug and 25% decrease in median Cl.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F175158"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Intelec er | Reminyl | Reminyl er</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Galantamin actavis | Galantamin easypharm | Galantamin krka | Galantamin Ratiopharm | Galantamin sandoz | Nivalin | Reminyl</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo galantamine | Galantamine an | Galantyl | Gamine | Reminyl</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Galantamine apotex | Galantamine eg | Galantamine mylan | Galantamine Sandoz | Galantamine teva | Reminyl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Galantagamma | Nivalin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alzynamin | Bromidrato de galantamina | Clometine | Cogit | Coglive | Elatium | Gaudy | Regressa | Reminyl | Reminyl er</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Galantamin helvepharm | Galantamin SR zentiva | Reminyl</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Galanvitae | Reminyl er</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Galanthamine hydrobromide | Hui min | Jin kang ling li | Qi er neng | Shi wei bao | Yi you li ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Antamin | Reminyl | Reminyl er</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Galant | Galantamin mylan | Galantamin Teva | Reminyl</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Galanaxiro | Galantagamma | Galantamin | Galantamin 1A pharma | Galantamin Aaa | Galantamin actavis | Galantamin AL | Galantamin CT | Galantamin glenmark | Galantamin heumann | Galantamin Hexal | Galantamin hormosan | Galantamin Neurax | Galantamin Ratiopharm | Galantamine mylan | Galnora | Nivalin | Reminyl</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Reminyl | Reminyl er</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Reminyl er</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Galantamin 1A pharma | Galsya | Reminyl</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Famalzyl | Reminyl</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Galantamina Actavis | Galantamina amneal | Galantamina Apotex | Galantamina cinfa | Galantamina combix | Galantamina Kern | Galantamina Mylan | Galantamina normon | Galantamina Ratiopharm | Galantamina Sandoz | Galantamina stada | Galantamina Teva | Galantamina tevagen | Galnora | Reminyl</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Galantamin actavis | Galantamin krka | Galantamin mylan | Galantamin orion | Galantamin Stada | Galantamine teva | Reminyl</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Galantamine | Galantamine Arrow | Galantamine Biogaran | Galantamine cristers | Galantamine eg | Galantamine krka | Galantamine mylan | Galantamine Sandoz | Galantamine teva | Galantamine Zydus | Reminyl | Reminyl LP</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Acumor | Consion XL | Elmino xl | Gaalin | Galantamine | Galantex | Galsya | Galzemic | Gatalin | Gazylan | Luventa | Reminyl | Zeebral XL</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Galantamine | Galantamine /Pharmathen | Galanyl | Memo-Farmellas | Memoton Life | Micol raldex | Reminyl | Zoroflog</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Galsya | Reminyl</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Galamer | Galamer od</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Galnora | Reminyl</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Galantamine | Galanyl Pr | Reminyl | Reminyl pr | Tamirin | Tamirin sr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Galsya | Nivalin | Reminyl</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Galantamine mylan | Reminyl</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Galsya | Nivalin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Reminyl | Reminyl er</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Galantamine | Galantamine actavis | Galantamine CF | Galantamine mylan | Galantamine Sandoz | Galantamine teva | Reminyl</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Galantamin krka | Reminyl</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Galantyl | Reminyl</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Galanvitae sr | Numencial | Reminyl | Reminyl er</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dementio | Dementio er | Reminyl</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Galantamine | Galantamine Hbr | Razadyne | Razadyne er</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Galantamina | Galantamina Actavis | Galantamina Aurovitas | Galantamina ciclum | Galantamina Generis | Galantamina Krka | Galantamina Labesfal | Galantamina Mylan | Galantamina Ratiopharm | Galantamina Sandoz | Galantamina Teva | Galantamina Wynn | Galantamina zentiva | Reminyl</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Galantamina | Reminyl er</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Galantamina zentiva | Galsya | Reminyl</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Galantamin Teva | Galantamine | Galantamine canon | Galnora sr | Nivalin | Reminyl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pms galantamine | Reminyl</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Galantamin abacus medicine | Galantamin actavis | Galantamin krka | Galantamin mylan | Galantamin orion | Galantamin sandoz | Galantamin Stada | Galantamin Teva | Indukolin | Reminyl</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Galantamin Teva | Galsya | Gazylan | Reminyl</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Galantamin mylan | Galantamin Teva | Galsya | Reminyl</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Galantamine symgens | Reminyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Reminyl</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Galantamina normon | Galtamin | Reminyl</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Proneurax</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Newgala</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Remcept xl | Reminyl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14533126">
<a name="14533126"></a>Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. <i>Int J Geriatr Psychiatry</i>. 2003;18(10):937-941.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/14533126/pubmed" id="14533126" target="_blank">14533126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APO-Galantamine.1">
<a name="APO-Galantamine.1"></a>APO-Galantamine (galantamine hydrobromide) [product monograph]. Weston, Ontario, Canada: Apotex Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17664404">
<a name="17664404"></a>Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: a randomized trial. <i>Neurology</i>. 2007;69(5):448-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/17664404/pubmed" id="17664404" target="_blank">17664404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19042161">
<a name="19042161"></a>Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. <i>Lancet Neurol</i>. 2009;8(1):39-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/19042161/pubmed" id="19042161" target="_blank">19042161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26918649">
<a name="26918649"></a>Chen YD, Zhang J, Wang Y, Yuan JL, Hu WL. Efficacy of cholinesterase inhibitors in vascular dementia: an updated meta-analysis. <i>Eur Neurol</i>. 2016;75(3-4):132-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/26918649/pubmed" id="26918649" target="_blank">26918649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17409748">
<a name="17409748"></a>Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. <i>Dement Geriatr Cogn Disord</i>. 2007;23(6):401-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/17409748/pubmed" id="17409748" target="_blank">17409748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14674789">
<a name="14674789"></a>Farlow MR. Clinical pharmacokinetics of galantamine. <i>Clin Pharmacokinet</i>. 2003;42(15):1383-1392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/14674789/pubmed" id="14674789" target="_blank">14674789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-West-Ward.1">
<a name="West-Ward.1"></a>Galantamine (galantamine hydrobromide oral solution, USP) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Galantamine (galantamine tablets, USP) [prescribing information]. Weston, FL: Apotex Corp; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831773">
<a name="20831773"></a>Hort J, O'Brien JT, Gainotti G, et al. EFNS Guidelines for the Diagnosis and Management of Alzheimer’s Disease. <i>Eur J Neurol</i>. 2010;17(10):1236-1248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/20831773/pubmed" id="20831773" target="_blank">20831773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18975103">
<a name="18975103"></a>Litvinenko IV, Odinak MM, Mogil'naya VI, et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). <i>Neurosci Behav Physiol</i>. 2008;38(9):937-945.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/18975103/pubmed" id="18975103" target="_blank">18975103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11396870">
<a name="11396870"></a>Morris JC, Farlow MR, Ferris SH, et al. Therapeutic Continuity in Alzheimer's Disease: Switching Patients to Galantamine. Panel Discussion: Recommendations for Prescribers. <i>Clin Ther</i>. 2001;23(suppl A):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/11396870/pubmed" id="11396870" target="_blank">11396870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline 97. https://www.nice.org.uk/guidance/ng97/evidence/full-guideline-pdf-4852695709. Published June 2018. Accessed March 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2">
<a name="NICE.2"></a>National Institute for Health and Care Excellence (NICE). Parkinson’s disease in adults. NICE guideline 71. https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061. Published July 2017. Accessed March 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28103749">
<a name="28103749"></a>O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2017;31(2):147-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/28103749/pubmed" id="28103749" target="_blank">28103749</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  PAT-galantamine ER (galantamine extended-release) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18340692">
<a name="18340692"></a>Rabins PV, Blacker D, Rovner BW, et al; APA Work Group on Alzheimer's Disease and other Dementias; Steering Committee on Practice Guidelines. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. <i>Am J Psychiatry</i>. 2007;164(12)(suppl):5-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/18340692/pubmed" id="18340692" target="_blank">18340692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881250">
<a name="10881250"></a>Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month Randomized, Placebo-Controlled Trial With a 6-month Extension. The Galantamine USA-1 Study Group, <i>Neurology</i>, 2000;54(12):2261-2268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/10881250/pubmed" id="10881250" target="_blank">10881250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Razadyne.1">
<a name="Razadyne.1"></a>Razadyne and Razadyne ER (galantamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11129124">
<a name="11129124"></a>Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. <i>Drugs</i>. 2000;60(5):1095-1122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/11129124/pubmed" id="11129124" target="_blank">11129124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881251">
<a name="10881251"></a>Tariot PN, Solomon PR, Morris JC, et al. A 5-month, Randomized, Placebo-controlled Trial of Galantamine in AD. The Galantamine USA-10 Study Group. <i>Neurology</i>. 2000;54(12):2269-2276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/galantamine-drug-information/abstract-text/10881251/pubmed" id="10881251" target="_blank">10881251</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8739 Version 342.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
